Army Science Board

Two Six Technologies Appoints Teresa Shea to Board of Directors

Retrieved on: 
Friday, January 26, 2024
United States Intelligence Community, SIGINT, Signals intelligence, DNI, IC, Central Intelligence, Johns Hopkins University, ZeroFox, Army Science Board, Security agency, CODEX, NSA, Georgia Tech, Defense, Defence Medal, Electricity, Intelligence, In-Q-Tel, Management

ARLINGTON, Va., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Two Six Technologies, a high-growth technology company providing products and expertise to national security customers, announced it has appointed Teresa Shea to its board of directors.

Key Points: 
  • ARLINGTON, Va., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Two Six Technologies, a high-growth technology company providing products and expertise to national security customers, announced it has appointed Teresa Shea to its board of directors.
  • Shea brings invaluable experience and unique perspectives to Two Six Technologies from her distinguished 32-year career with the National Security Agency (NSA).
  • She held several key leadership assignments during her NSA career, culminating as the Director of Signals Intelligence.
  • “We are extremely excited to welcome Teresa to our board to help us grow our impact across the Intelligence Community (IC),” said Larry Prior, Chairman of the Board, Two Six Technologies.

Versameb Names Dr. Alexandre LeBeaut as Chair of the Board of Directors

Retrieved on: 
Tuesday, December 5, 2023
SUI, Patient, FDA, Army Science Board, Investigational New Drug, Novartis, Therapy, CSL Vifor, Gastroenterology, MD, Trial of the century, Ipsen, Biology, RNA, Medical device

BASEL, Switzerland, Dec. 5, 2023 /PRNewswire/ -- Versameb AG ("Versameb"), a pre-clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced that its Board of Directors has unanimously appointed of Dr. Alexandre LeBeaut, MD as Chairman of the Board, effective immediately.

Key Points: 
  • BASEL, Switzerland, Dec. 5, 2023 /PRNewswire/ -- Versameb AG ("Versameb"), a pre-clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced that its Board of Directors has unanimously appointed of Dr. Alexandre LeBeaut, MD as Chairman of the Board, effective immediately.
  • Dr. LeBeaut has over two decades of global R&D leadership experiences, successfully bringing multiple medicines to market in immunology, oncology, gastroenterology, cardio-metabolic and infectious diseases.
  • Dr. Alexandre LeBeaut, new Chairman of the Board of Directors of Versameb, commented: "I am honored to take this responsibility as Chair of Versameb's board at such a pivotal time in company's growth trajectory.
  • He is currently an Independent Director of Calypso Biotech (Geneva, Switzerland), OSE Immunotherapeutics (Paris, France) and ImmunoRx Pharma (Wilmington, DE).

Versameb Names Dr. Alexandre LeBeaut as Chair of the Board of Directors

Retrieved on: 
Tuesday, December 5, 2023
SUI, Patient, FDA, Army Science Board, Investigational New Drug, Novartis, Therapy, CSL Vifor, Gastroenterology, MD, Trial of the century, Ipsen, Biology, RNA, Medical device

BASEL, Switzerland, Dec. 5, 2023 /PRNewswire/ -- Versameb AG ("Versameb"), a pre-clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced that its Board of Directors has unanimously appointed of Dr. Alexandre LeBeaut, MD as Chairman of the Board, effective immediately.

Key Points: 
  • BASEL, Switzerland, Dec. 5, 2023 /PRNewswire/ -- Versameb AG ("Versameb"), a pre-clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced that its Board of Directors has unanimously appointed of Dr. Alexandre LeBeaut, MD as Chairman of the Board, effective immediately.
  • Dr. LeBeaut has over two decades of global R&D leadership experiences, successfully bringing multiple medicines to market in immunology, oncology, gastroenterology, cardio-metabolic and infectious diseases.
  • Dr. Alexandre LeBeaut, new Chairman of the Board of Directors of Versameb, commented: "I am honored to take this responsibility as Chair of Versameb's board at such a pivotal time in company's growth trajectory.
  • He is currently an Independent Director of Calypso Biotech (Geneva, Switzerland), OSE Immunotherapeutics (Paris, France) and ImmunoRx Pharma (Wilmington, DE).

TOM RUTLEDGE TO BECOME BOARD MEMBER EMERITUS, ERIC ZINTERHOFER APPOINTED NON-EXECUTIVE CHAIRMAN OF THE BOARD, CHRIS WINFREY APPOINTED TO CHARTER COMMUNICATIONS' BOARD

Retrieved on: 
Wednesday, October 25, 2023
Television, Harvard Business School, Vehicle and Operator Services Agency, Vodafone Germany, ATC, Hugh Campbell Distinguished Leadership Award, Gesellschaft mit beschränkter Haftung, Time Warner Cable, Apollo, Cable, History, Altice USA, Charter Communications, Corporate finance, Searchlight Capital, NTL Incorporated, University, Eastern Communications, Communication, Satellite Television & Associated Resources, UPC Switzerland, Senior, Apollo Global Management, Retirement, Lead, Army Science Board, Finance, Charter, CHTR, NCTA, Management, Economics

The Board also appointed Charter's President and Chief Executive Officer, Chris Winfrey to the Board to fill the vacancy created upon Mr. Rutledge's retirement.

Key Points: 
  • The Board also appointed Charter's President and Chief Executive Officer, Chris Winfrey to the Board to fill the vacancy created upon Mr. Rutledge's retirement.
  • The Board appointed Charter's Lead Independent Director, Eric Zinterhofer as non-executive Chairman of the Board effective November 30, 2023.
  • "I am very pleased that Tom has agreed to stay on as Board Member Emeritus," said Mr. Winfrey.
  • "I look forward to returning to the Chairman role and welcome Chris to the Board," said Mr. Zinterhofer.

Peabody Elects Dr. M. Katherine Banks to Board of Directors

Retrieved on: 
Monday, October 16, 2023
Halliburton, NYSE, Engineering, Security, Texas A&M University, National Academy of Engineering of Korea, Society, University of North Carolina at Charlotte, University, Steel, National academy, Butte Citizens Technical Environmental Committee, Peabody, Army Science Board, United States national laboratories, Duke University, BTU, American Society of Civil Engineers, Audit committee, Management, Safety

ST. LOUIS, Oct. 16, 2023 /PRNewswire/ -- Peabody today announced that Dr. M. Katherine Banks has been appointed as a member of the company's Board of Directors.

Key Points: 
  • ST. LOUIS, Oct. 16, 2023 /PRNewswire/ -- Peabody today announced that Dr. M. Katherine Banks has been appointed as a member of the company's Board of Directors.
  • "We welcome Dr. Banks to the Board of Directors.
  • Her impressive background in engineering and long record of academic leadership will bring a unique perspective that will strengthen Peabody's diverse board," Peabody Chairman of the Board Bob Malone said.
  • Peabody (NYSE: BTU) is a leading coal producer, providing essential products for the production of affordable, reliable energy and steel.

Cabot Corporation Announces Changes to Board of Directors

Retrieved on: 
Friday, September 15, 2023
Chemicals, Plastics, Manufacturing, Management development, National Executive Committee of the Labour Party, ASC Technology Committee, Acrylate, Army Science Board, Cabot Corporation, Compensation, PMMA, Arkema, Strategic planning, Audit committee, Wilson, Retirement, Corporation, Brady Corporation, Committee, Global Media & Entertainment, Growth, NYSE, Chair, Management

Cabot Corporation (NYSE: CBT) announced today that Michelle Williams, Ph.D., has been elected to its Board of Directors , effective September 13, 2023.

Key Points: 
  • Cabot Corporation (NYSE: CBT) announced today that Michelle Williams, Ph.D., has been elected to its Board of Directors , effective September 13, 2023.
  • She was also appointed a member of the Audit Committee of the Board of Directors, effective September 13, 2023.
  • Sue H. Rataj, Non-Executive Chair of Cabot’s Board of Directors, said, “We are very pleased to welcome Michelle to our Board.
  • With Dr. Williams’ election to the Board, Sue Rataj advised the Company that she would be retiring from the Board effective May 31, 2024.

PaxMedica Appoints David Hough M.D. as Chief Medical Officer

Retrieved on: 
Wednesday, August 16, 2023
Geriatric psychiatry, Lead, Drug development, IV, DSM-IV codes, Army Science Board, Schizophrenia, Autism spectrum, INVEGA, CMO, Doctor of Philosophy, ASD, Spectrum, Johnson & Johnson, APT, Janssen Pharmaceuticals, Psychiatry, Pharmaceutical industry, Management

TARRYTOWN, NY, Aug. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms, today announced the return of David Hough, M.D., as Chief Medical Officer (CMO) of PaxMedica, effective immediately.  Dr. Hough  has been a key consultant to the company during 2023 and was the company’s CMO from 2020-2022. He is board-certified in both adult and geriatric psychiatry.  He succeeds Stefan Schwabe M.D., PhD, who will continue to serve on the PaxMedica Scientific Advisory Board.

Key Points: 
  • PaxMedica also announced additional changes to the management team and Board of Directors, all effective as of August 21, 2023.
  • Howard Weisman, Chief Executive Officer of PaxMedica, has been appointed to the additional position of Chairman of the Board of Directors.
  • Stephen Sheldon has been appointed to the role of Chief Operating Officer in addition to his position as Chief Financial Officer.
  • We are delighted to welcome him back to PaxMedica as Chief Medical Officer,” added Howard Weisman, PaxMedica’s Chairman and CEO.

Armis Establishes Federal Advisory Board to Support Demand in its Public Sector Business Growth

Retrieved on: 
Tuesday, June 6, 2023
Technology, Homeland Security, 5G, Security, Public Policy, Government, Software, Internet, White House, Federal Government, IOT (Internet of Things), Under Secretary of State for Public Diplomacy and Public Affairs, Public affairs, Face, Internet of things, Senior advisor, Airport, United States Department of State, IL4, ICS, Public sector, Public diplomacy, IoMT, CIO, Federation, United States Department of Veterans Affairs, FedRAMP, Environment, Insight Partners, Risk management, Army Science Board

Armis, the leading asset visibility and security company, today announced the formation of the Armis Federal Advisory Board, a senior group of former government executives charged with providing strategic guidance and direction to the Armis executive team.

Key Points: 
  • Armis, the leading asset visibility and security company, today announced the formation of the Armis Federal Advisory Board, a senior group of former government executives charged with providing strategic guidance and direction to the Armis executive team.
  • The Board members have extensive experience in both technology and the federal government and will provide objective advice and guidance on how Armis can better support the government’s changing security needs.
  • Their input will be vital as Armis continues to defend government networks against escalating threats,” said Brian Gumbel, President of Armis.
  • If you would like to know more about Armis' award-winning solutions for the public sector, visit Armis.com or contact us here .

HUYA Inc. Announces Changes to Board Composition

Retrieved on: 
Tuesday, May 23, 2023
Open Platform, Tianjin University, Army Science Board, MBA, China Europe International Business School, QQ, NYSE, Management, Tencent, CEIBS

Mr. Lingdong Huang no longer serves as a director and the chairman of the Board or as a member of any Board committees of Huya following this substitution.

Key Points: 
  • Mr. Lingdong Huang no longer serves as a director and the chairman of the Board or as a member of any Board committees of Huya following this substitution.
  • In addition, Huya's Board has approved the appointment of Mr. Songtao Lin as the chairman of the Board and a member of the Board's nominating and corporate governance committee, effective immediately.
  • The Board is pleased to welcome Mr. Songtao Lin and looks forward to adding Mr. Lin's expertise and perspectives to Huya's Board.
  • The Board would also like to express its sincere gratitude to Mr. Lingdong Huang for his commitment and contributions to Huya over the past few years.

HUYA Inc. Announces Changes to Board Composition

Retrieved on: 
Tuesday, April 11, 2023
Army Science Board, HKSE, Sun, Huya, NYSE, Economics, Management, Tencent

GUANGZHOU, China, April 11, 2023 /PRNewswire/ -- HUYA Inc. (NYSE: HUYA) ("Huya" or the "Company"), a leading game live streaming platform in China, today announced that Mr. Qinghua Xie has been appointed by Linen Investment Limited, a wholly-owned subsidiary of Tencent Holdings Limited ("Tencent"), as a successor director to serve on Huya's board of directors (the "Board"), replacing Mr. Cheng Yun Ming Matthew, effective April 10, 2023.

Key Points: 
  • GUANGZHOU, China, April 11, 2023 /PRNewswire/ -- HUYA Inc. (NYSE: HUYA) ("Huya" or the "Company"), a leading game live streaming platform in China, today announced that Mr. Qinghua Xie has been appointed by Linen Investment Limited, a wholly-owned subsidiary of Tencent Holdings Limited ("Tencent"), as a successor director to serve on Huya's board of directors (the "Board"), replacing Mr. Cheng Yun Ming Matthew, effective April 10, 2023.
  • Mr. Cheng no longer serves as a director of the Board or a member of any Board committees of Huya following this substitution.
  • In addition, Huya's Board has approved the appointment of Mr. Xie as a member and the chairman of the compensation committee of the Board, effective immediately.
  • Mr. Qinghua Xie joined Tencent in December 2003, and currently serves as the corporate vice president of Tencent.